Discovery and hit to lead optimization of novel combretastatin A-4 analogues: Dependence of C-linker length and hybridization

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 10, 2013, Pages 1614-1635

  Provot, Olivier ^a   Hamze, Abdallah ^a   Peyrat, Jean François ^a   Brion, Jean Daniel ^a   Alami, Mouad ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Apoptosis; Binding; Combretastatin A 4; Cytotoxicity; isoCA 4; Linker; Tubulin

Indexed keywords

1,1 DIARYLETHYLENE DERIVATIVE; ALKENE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZIL DERIVATIVE; BENZOXEPIN DERIVATIVE; CHALCONE; COMBRETASTATIN A4; COMBRETASTATIN A4 DERIVATIVE; DIKETONE; DRUG ANALOG; ENEDIYNE; ENYNE DERIVATIVE; ERIANIN; NAPHTHALENE DERIVATIVE; PHENSTATIN; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PRODRUG; TUBULIN; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHRONIC MYELOID LEUKEMIA; CONFORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IC 50; LUNG NON SMALL CELL CANCER; MICROTUBULE ASSEMBLY; MICROWAVE IRRADIATION; MOLECULAR DOCKING; MOLECULAR HYBRIDIZATION; OXIDATION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TUBULIN POLYMERIZATION ASSAY; UMBILICAL VEIN ENDOTHELIAL CELL; UTERINE CERVIX CARCINOMA; X RAY CRYSTALLOGRAPHY;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BIBENZYLS; CELL LINE, TUMOR; CELL PROLIFERATION; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG DESIGN; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; G2 PHASE CELL CYCLE CHECKPOINTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LAMININ; MOLECULAR STRUCTURE; PROTEOGLYCANS; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN MODULATORS;

EID: 84897467959     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152061310131206162302     Document Type: Article

References (111)

1. Pettit, G.; Singh, S.B.; Hamel, E.; Lin, C.M.; Alberts, D.S.; Garcia- Kendall, D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia, 1989, 45, 209-211.
2. Sackett, D.L. Podophyllotoxin, steganacin and combretastatin: Natural products that bind at the colchicine site of tubulin. Pharmacol. Ther., 1993, 59, 163-228.
3. Xia, Y.; Yang, Z.-Y.; Xia, P.; Bastow, K.F.; Tachibana, Y.; Kuo, S.-C.; Hamel, E.; Hackl, T.; Lee, K.-H. Antitumor agents. 181. Synthesis and biological evaluation of 6,7,2',3',4'-substituted- 1,2,3,4-tetrahydro-2-phenyl-4-quinolones as a new class of antimitotic antitumor agents. J. Med. Chem., 1998, 41, 1155-1162.
4. Mc Gown, A.T.; Fox, B.W. Differential cytotoxicity of combretastatins A1 and A4 in two daunorubucin-resistant P388 cell lines. Cancer Chemother. Pharmacol. 1990, 26, 79-81.
5. Dark, G.G.; Hill, S.A.; Prise, V.E.; Tozer, G.M.; Pettit, G.R.; Chaplin, D.J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res., 1997, 57, 1829-1834.
6. Griggs, J.; Metcalfe J.C.; Hesketh, R. Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol., 2001, 2, 82-87.
7. Ohsumi, K.; Nakagawa, R.; Fukuda, Y.; Hatanaka, T.; Morinaga, Y.; Nihei, Y.; Ohishi, K.; Suga, Y.; Akiyama, Y.; Tsuji, T. Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J. Med. Chem. 1998, 41, 3022-3032.
8. Pettit, G.R.; Toki, B.E.; Herald, D.L.; Boyd, M.R.; Hamel, E.; Pettit R.K.; Chapuis, J.-C. Antineoplastic agents. 410. Asymmetric hydroxylation of trans-combretastatin A-4. J. Med. Chem. 1999, 42, 1459-1465.
9. Pettit, G.R.; Rhodes, M.R.; Herald, D.L.; Chaplin, D.J.; Stratford, M.R.; Hamel, E.; Pettit, R.K.; Chapuis, J.-C.; Oliva, D. Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug. Anti-Cancer Drug Des., 1998, 13, 981-993.
10. Aprile, S.; Del Grosso, E.; Tron G.C.; Grosa, G. In vitro metabolism study of combretastatin A-4 in rat and human liver microsomes. Drug Metab. Dispos., 2007, 35, 2252-2261.
11. Galbraith, S.M.; Maxwell, R.J.; Lodge, M.A. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J. Clin. Oncol., 2003, 21, 2831-2842.
12. Anderson, H.L.; Yap, J.T.; Miller, M.P.; Robbins, A.; Jones, T.; Price, P.M. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J. Clin. Oncol., 2003, 21, 2828-2830.
13. Ohno, T.; Kawano, K.; Sasaki, A.; Aramaki, M.; Tahara, K.; Etoh, T.; Kitano, S. Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer. Int. J. Clin. Oncol., 2002, 7, 171-176.
14. Banerjee, S.; Wang, Z.; Mohammad, M.; Sarkar, F.H.; Mohammad, R.M. Efficacy of selected natural products as therapeutic agents against cancer. J. Nat. Prod., 2008, 71, 492-496.
15. Rustin, G.J.; Galbraith, S.; Anderson, H.; Stratford, M.; Folkes, L.K.; Sena, L.; Gumbrell, L.; Price, P.M. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol., 2003, 21, 2815-2822.
16. Nam, N.H. Combretastatin A-4 analogues as antimitotic antitumor agents. Curr. Med. Chem., 2003, 10, 1697-1722and references therein.
17. Tron, G.C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A.A. Medicinal chemistry of combretastatin A4: present and future directions. J. Med. Chem., 2006, 49, 3033-3044.
18. Pattillo, C.B. Combretastatin derivatives in cancer: Recent research reviewed. Drugs Fut., 2011, 36, 385-390.
19. Cirla, A.; Mann, J. Combretastatins: From natural products to drug discovery. Nat. Prod. Rep., 2003, 20, 558-564.
20. Shan, Y.; Zhang, J.; Liu, Z.; Wang, M.; Dong, Y. Developments of combretastatin A-4 derivatives as anticancer agents. Curr. Med. Chem., 2011, 18, 523-538.
21. Marelli, M.; Conforti, F.; Statti, G.A.; Cachet, X.; Michel, S.; Tillequin, F.; Menichini, F. Biological potential and structureactivity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin A-4. Curr. Med. Chem. 2011, 18, 3035-3081.
22. Cushman, M.; Nagarathnam, D.; Gopal, D.; Chakraborti, A.K.; Lin, C.; Hamel, E. Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization J. Med. Chem., 1991, 34, 2579-2588.
23. Lawrence, N.J.; Rennison, D.; Woo, M.; McGown, A.T.; Hadfield, J.A. Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers. Bioorg. Med. Chem. Lett., 2001, 11, 51-54.
24. Giraud, A; Provot, O.; Hamze, A.; Brion, J.D.; Alami, M. One-pot hydrosilylation-protodesilylation of functionalized diarylalkynes: a highly selective access to Z-stilbenes. Application to the synthesis of combretastatin A-4. Tetrahedron Lett., 2008, 49, 1107-1110.
25. Provot, O.; Giraud, A.; Peyrat, J.F.; Alami, M.; Brion, J.D. Synthetic approach to enyne and enediyne analogues of anticancer agents. Tetrahedron Lett., 2005, 46, 8547-8550.
26. Smith, A.L.; Nikolaou, K.C. The enediyne antibiotics. J. Med. Chem. 1996, 39, 2103-2017.
27. Sonogashira, K. Tohda, Y., Hagihara, N. A convenient synthesis of acetylenes: catalytic substitutions of acetylenic hydrogen with bromoalkenes, iodoarenes and bromopyridines. Tetrahedron Lett., 1975, 4467-4470.
28. Alami, M.; Ferri, F.; Linstrumelle, G. An efficient palladiumcatalysed reaction of vinyl and aryl halides or triflates with terminal alkynes. Tetrahedron Lett. 1993, 34, 6403-6406.
29. Alami, M.; Peyrat, J.F., Brion, J.D. 1,2-Dihalogenalkenes: Useful Linchpins to Unsaturated Compounds via Palladium or Nickel Catalysis. Synthesis, 2000, 1499-1518.
30. Alami, M.; Ferri, F.; Gaslain, Y. A two-step synthesis of terbinafine. Tetrahedron Lett., 1996, 37, 57-58.
31. Alami, M.; Crousse, B.; Ferri, F. Weakly Ligated Palladium Complexes PdCl2(RCN)2 in Piperidine: Versatile Catalysts for Sonogashira Reaction of Vinyl Chlorides at Room Temperature. J. Organomet. Chem., 2001, 624, 114-123.
32. Lo, Y.H.; Lin, C.C.; Lin, C.F.; Lin, Y.T.; Hong, Y.R.; Yang, S.H.; Lin, S.R.; Yang, S.C.; Chang, L.S.; Wu, M.J. 2-(6-aryl-3(Z)-hexen- 1,5-diynyl)anilines as a new class of potent antitubulin agents. J. Med. Chem., 2008, 51, 2682-2688.
33. Alami, M.; Ramiandrasa, P.; Cahiez, G. Manganese halidescatalyzed selective cross coupling reaction of unsaturated vinyl chlorides with grignard reagents. Synlett, 1998, 325-327.
34. Peyrat, J.-F.; Thomas, E.; L'Hermite, N.; Alami, M.; Brion, J.-D. Versatile palladium(II)-catalyzed Negishi coupling reactions with functionalized conjugated alkenyl chlorides. Tetrahedron Lett., 2003, 44, 6703-6707.
35. Seck, M.; Franck, X.; Hocquemiller, R.; Figadère, B.; Peyrat, J.F.; Provot, O.; Brion, J.D.; Alami, M. Synthesis of substituted quinolines by iron-catalyzed coupling reactions between chloroenynes and Grignard reagents. Tetrahedron Lett., 2004, 45, 1881-1884.
36. Dos Santos, M.; Franck, X.; Hocquemiller, R.; Figadère, B.; Peyrat, J.F.; Provot, O.; Brion, J.D.; Alami, M. Iron-catalyzed coupling reaction between 1,1-dichloro-1-alkenes and grignard reagents. Synlett, 2004, 15, 2697-2700.
37. Kaffy, J.; Pontikis, R.; Florent, J.C.; Monneret, C. Synthesis and biological evaluation of vinylogous combretastatin A-4 derivatives. Org. Biomol. Chem., 2005, 3, 2657-2660.
38. Pettit, G. R.; Toki, B.; Herald, D.L.; Verdier-Pinard, P.; Boyd, E.; Hamel, M.R.; Pettit, R.K. Antineoplastic agents. 379. Synthesis of phenstatin phosphate. J. Med. Chem., 1998, 41, 1688-1695.
39. Liou, J.P.; Chang, C.W.; Song, J.-S.; Yang, Y.N.; Yeh, C.F.; Tseng, H.Y.; Lo, Y.K.; Chang, Y.L; Chang, C.M.; Hsieh, H.P. Synthesis and structure-activity relationship of 2- aminobenzophenone derivatives as antimitotic agents. J. Med. Chem., 2002, 45, 2556-2562.
40. Liou, J.P.; Chang, J.Y.; Chang, C.W.; Chang, C.Y.; Mahindroo, N.; Kuo, F.M.; Hsieh, H.P. Synthesis and structure-activity relationships of 3-aminobenzophenones as antimitotic agents. J. Med. Chem., 2004, 47, 2897-2905.
41. Ducki, S.; Hadfield, J.A.; Lawrence, N.J.; Liu, C.Y.; McGown, A.T.; Rennison, D. Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg. Med. Chem. Lett., 1998, 8, 1051-1056.
42. Lawrence, N.J.; McGown, A.T.; Ducki, S.; Hadfield, J.A. The interaction of chalcones with tubulin. Anti-Cancer Drug Des., 2000, 15, 35-41.
43. Ducki, S.; Mackenzie, G.; Greedy, B.; Armitage, S.; Fournier Dit Chabert, J.; Bennett, E.; Nettles, J.; Snyder, J.P.; Lawrence, N.J. Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones. Bioorg. Med. Chem., 2009, 17, 7711-7722.
44. Giraud, A.; Provot, O.; Peyrat, J.F.; Alami, M.; Brion, J.D. Microwave-assisted efficient synthesis of 1,2-diaryldiketones: a novel oxidation reaction of diarylalkynes with DMSO promoted by FeBr3. Tetrahedron, 2006, 62, 7667-7673.
45. Mousset, C.; Provot, O.; Hamze, A.; Bignon, J.; Brion, J.D.; Alami, M. DMSO-PdI2 as a powerful oxidizing couple of alkynes into benzils: one-pot synthesis of nitrogen-containing five- or sixmembered heterocycles. Tetrahedron, 2008, 64, 4287-4294.
46. Mousset, C.; Giraud, A.; Provot, O.; Hamze, A.; Bignon, J.; Liu, J.M.; Thoret, S.; Dubois, J.; Brion, J.D.; Alami, M. Synthesis and antitumor activity of benzils related to combretastatin A-4. Bioorg. Med. Chem. Lett., 2008, 18, 3266-3271.
47. Lin, C.M.; Ho, H.H.; Pettit, G.R.; Hamel, E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry, 1989, 28, 6984-6991.
48. Pettit, G.R.; Temple, C., Jr.; Narayanan, V.L.; Varma, R.; Boyd, M.R.; Rener, G.A.; Bansal, N. Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des., 1995, 10, 299-309.
49. Boatright, K.M.; Salvesen, G.S. Mechanisms of caspase activation. Curr. Opin. Cell. Biol., 2003, 15, 725-731.
50. Pettit, G.R.; Singh, S.B.; Boyd, M.R.; Hamel, E.; Pettit, R.K.; Schmidt, J.M.; Hogan, F. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a). J. Med. Chem. 1995, 38, 1666-1672.
51. Lin, C.M.; Singh, S.B.; Chu, P.S.; Dempcy, R.O.; Schmidt, J.M.; Pettit, G.R.; Hamel, E. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: A structure-activity study. Mol. Pharmacol., 1988, 34, 200-208.
52. Gong, Y.-Q.; Fan, Y., Wu, D.Z.; Yang, H.; Hu, Z.-B.; Wang, Z.-T. In vivo and in vitro evaluation of erianin, a novel anti-angiogenic agent. Eur. J. Cancer, 2004, 40, 1554-1565.
53. Shirai, R.; Tokuda, K.; Koiso, Y.; Shigeo, I. Synthesis and ntitubulin activity of aza-combretastatins. Bioorg. Med. Chem. Lett., 1994, 4, 699-704.
54. Messaoudi, S.; Tréguier, B.; Hamze, A.; Provot, O.; Peyrat, J.F.; Rodrigo De Losada, J.; Liu, J.M.; Bignon, J.; Wdzieczak-Bakala, J.; Thoret, S.; Dubois, J.; Brion, J.D.; Alami, M. Isocombretastatins-A versus combretastatins-A: the forgotten isoCA-4 isomer as a highly promising cytotoxic and antitubulin agent. J. Med. Chem., 2009, 52, 4538-4542.
55. Barluenga, J.; Moriel, P.; Valdés, C.; Aznar, F. N-tosylhydrazones as reagents for cross-coupling reactions: A route to polysubstituted olefins. Angew. Chem., Int. Ed., 2007, 46, 5587-5590.
56. Tréguier, B.; Hamze, A.; Provot, O.; Brion, J.D.; Alami, M. Expeditious synthesis of 1,1-diarylethylenes related to isocombretastatin A-4 (isoCA-4) via palladium-catalyzed arylation of N-tosylhydrazones with aryl triflates. Tetrahedron Lett., 2009, 50, 6549-6552.
57. Hamze, A.; Veau, D.; Provot, O.; Brion, J.D.; Alami, M. Palladiumcatalyzed Markovnikov terminal arylalkynes hydrostannation: application to the synthesis of 1,1-diarylethylenes. J. Org. Chem., 2009, 74, 1337-1340.
58. Hamze, A.; Giraud, A.; Messaoudi, S.; Provot, O.; Peyrat, J.F.; Bignon, J.; Liu, J.M.; Wdzieczac-Bakala, J.; Thoret, S.; Dubois, J.; Brion, J.D.; Alami, M. Synthesis, biological evaluation of 1,1- diarylethylenes as a novel class of antimitotic agents. ChemMedChem, 2009, 4, 1912-1924.
59. Nakamura, H.; Kuroda, H.; Saito, H.; Suzuki, R.; Yamori, T.; Maruyama, K.; Haga, T. Synthesis and biological evaluation of boronic acid containing cis-stilbenes as apoptotic tubulin polymerization inhibitors. ChemMedChem, 2006, 1, 729-740.
60. Pinney, K.G.; Mejia, M.P.; Villalobos, V.M.; Rosenquist, B.E.; Pettit, G.R. Synthesis and biological evaluation of aryl azide derivatives of combretastatin a-4 as molecular probes for tubulin. Bioorg. Med. Chem., 2000, 8, 2417-2425.
61. Hamze, A.; Rasolofonjatovo, E.; Provot, O.; Mousset, C.; Veau, D.; Rodrigo, J.; Bignon, J.; Liu, J.M.; Wdzieczak-Bakala, J.; Thoret, S.; Dubois, J.; Brion, J.D.; Alami, M. B-Ring-modified isocombretastatin A-4 analogues endowed with interesting anticancer activities. ChemMedChem, 2011, 6, 2179-2191.
62. Olivi, N.; Thomas, E.; Peyrat, J.F.; Alami, M.; Brion, J.D. Highly efficient p-toluenesulfonic acid-catalyzed alcohol addition or hydration of unsymmetrical arylalkynes. Synlett, 2004, 2175-2179.
63. Le Bras, G.; Provot, O.; Peyrat, J.F.; Brion, J.D.; Alami, M. Rapid microwave assisted hydration of internal arylalkynes in the presence of PTSA: an efficient regioselective access to carbonyl compounds. Tetrahedron Lett., 2006, 47, 5497-5501.
64. Jacubert, M.; Hamze, A.; Provot, O.; Peyrat, J.F.; Brion, J.D.; Alami, M. p-Toluenesulfonic acid-mediated cyclization of o-(1- alkynyl)anisoles or thioanisoles: synthesis of 2-arylsubstituted benzofurans and benzothiophenes. Tetrahedron Lett., 2009, 50, 3588-3592.
65. Jacubert, M.; Provot, O.; Peyrat, J.F.; Hamze, A.; Brion, J.D.; Alami, M. p-Toluenesulfonic acid-promoted selective functionalization of unsymmetrical arylalkynes: A regioselective access to various arylketones and heterocycles. Tetrahedron, 2010, 66, 3775-3787.
66. Chang, M.P.; Bramhall, J.; Graves, S.; Bonavida, B.; Wisnieski, B.J. Internucleosomal DNA cleavage precedes diphtheria toxininduced cytolysis. Evidence that cell lysis is not a simple consequence of translation inhibition. J. Biol. Chem., 1989, 264, 15261-15267.
67. McGahon, A.; Bissonnette, R.; Schmitt, M.; Cotter, K.M.; Green, D.R.; Cotter, T.G. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood, 1994, 83, 1179-1187.
68. McGahon, A.J.; Nishioka, W.K.; Martin, S.J.; Mahboubi, A.; Cotter, T.G.; Green, D.R. Regulation of the Fas apoptotic cell death pathway by Abl. J. Biol. Chem., 1995, 270, 22625-22631.
69. Gangemi, R.M. Tiso, M. Marchetti, C. Severi, A.B. Fabbi, M. Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death. Cancer Chemother. Pharmacol., 1995, 36, 385-392.
70. Dubrez, L. Goldwasser, F. Genne, P. Pommier, Y. Solary, E. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia, 1995, 9, 1013-1024.
71. Ray, S.; Bullock, G.; Nunez, G.; Tang, C.; Ibrado, A.M.; Huang, Y.; Bhalla, K. Enforced expression of Bcl-XS induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-beta-D-arabinofuranosylcytosine-mediated differentiation and apoptosis. Cell Growth Diff., 1996, 7, 1617-1623.
72. Aziz, J.; Brachet, E.; Hamze, A.; Peyrat, J.F.; Bernadat, G.; Morvan, E.; Bignon, J.; Wdzieczak-Bakala, J.; Desravines, D.; Dubois, J.; Tueni, M.; Yassine, A.; Brion, J.D.; Alami, M. Synthesis, biological evaluation, and structure-activity relationships of tri- and tetrasubstituted olefins related to isocombretastatin A-4 as new tubulin inhibitors. Org. Biomol. Chem. 2013, 11, 430-442.
73. Bekaert, A.; Provot, O.; Rasolojahona, O.; Alami, M.; Brion, J.D. N-Methylpyrrolidin-2-one hydrotribromide (MPHT) a mild reagent for selective bromination of carbonyl compounds: synthesis of substituted 2-bromo-1-naphtols. Tetrahedron Lett., 2005, 46, 4187-4191.
74. Jacubert, M.; Tikad, A.; Provot, O.; Hamze, A.; Brion, J.D.; Alami, M. MPHT promoted bromocyclization of ortho-substituted arylalkynes: Application to the synthesis of 2-substituted-3-bromobenzofurans and benzo[b]thiophenes. Eur. J. Org. Chem. 2010, 4492-4500.
75. Giordano, C.; Castaldi, G.; Casagrande, F.; Abis, L. Silver assisted rearrangement of primary and secondary α-bromoalkylarylketones. Tetrahedron Lett., 1982, 23, 1385-1386.
76. Brachet, E.; Hamze, A.; Peyrat, J.F.; Brion, J.D.; Alami, M. Pdcatalyzed reaction of sterically hindered hydrazones with aryl halides: synthesis of tetra-substituted olefins related to isocombretastatin A-4. Org. Lett., 2010, 12, 4042-4045.
77. Rasolofonjatovo, E.; Provot, O.; Hamze, E.; Bignon, J.; Thoret, S.; Brion, J.D.; Alami, M. Regioselective hydrostannation of diarylalkynes directed by a labile ortho bromine atom: An easy access to stereodefined triarylolefins, hybrids of combretastatin A-4 and isocombretastatin A-4. Eur. J. Med. Chem., 2010, 45, 3617-3626.
78. Liron, F.; Le Garrec, P.; Alami, M. Regiochemical Control in the Hydrostannylation of Aryl-Substituted Alkynes. A Stereoselective Synthesis of Disubstituted Vinylstannanes. Synlett, 1999, 246-248.
79. Alami, M.; Liron, F.; Gervais, M.; Peyrat, J.F.; Brion, J.D. Ortho substituents direct regioselective addition of tributyltin hydride to unsymmetrical diaryl (or heteroaryl) alkynes: an efficient route to stannylated stilbene derivatives. Angew. Chem., Int. Ed., 2002, 41, 1578-1580.
80. Hamze, A.; Provot, O.; Brion, J.D.; Alami, M. Regiocontrol of the palladium-catalyzed tin hydride addition to Z-enynols: remarkable Z-directing effects. J. Org. Chem., 2007, 72, 3868-3874.
81. Ferri, F.; Alami, M. Expeditious stereo and regioselective synthesis of stannylated dienynes: Versatile precursors of dienediynes related to neocarzinostatin chromophore. Tetrahedron Lett., 1996, 37, 7971-7974.
82. Hamze, A.; Le Menez, P.; Provot, O.; Morvan, E.; Brion, J.D.; Alami, M. Regioselective hydrostannation of highly hindered arylalkynes under ortho-directing effects. Tetrahedron Lett., 2010, 66, 8698-8706.
83. Hamze, A.; Provot, O.; Brion, J.D.; Alami, M. Regiochemical aspects of the platinum oxide catalyzed hydrosilylation of alkynes. Synthesis, 2007, 2025-2036.
84. Liron, F.; Gervais, M.; Peyrat, J.F.; Alami, M.; Brion, J.D. Palladium-catalyzed stereoselective synthesis of E- and Z-1,1- diaryl or triarylolefins. Tetrahedron Lett.; 2003, 44, 2789-2794.
85. Bailly, C.; Bal, C.; Barbier, P.; Combes, S.; Finet, J.P.; Hildebrand, M.P.; Peyrot, V.; Wattez, N. Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. J. Med. Chem., 2003, 46, 5437-5444.
86. Ganina, O.G.; Daras, E.; Bourgarel-Rey, V.; Peyrot, V.; Andresyuk, A.N.; Finet, J.P.; Fedorov, A.Y.; Beletskaya, I.P.; Combes, S. Synthesis and biological evaluation of polymethoxylated 4- heteroarylcoumarins as tubulin assembly inhibitor. Bioorg. Med. Chem., 2008, 16, 8806-8812.
87. Sriram, M.; Hall, J.J.; Grohmann, N.C.; Strecker, T.E.; Wootton, T.; Franken, A.; Trawick, M.L.; Pinney, K. Design, synthesis and biological evaluation of dihydronaphthalene and benzosuberene analogs of the combretastatins as inhibitors of tubulin polymerization in cancer chemotherapy. Bioorg. Med. Chem., 2008, 16, 8161-8171.
88. Rasolofonjatovo, E.; Provot, O.; Hamze, A.; Rodrigo, J.; Bignon, J.; Wdzieczak-Bakala, J.; Desravines, D.; Dubois, J.; Brion, J.D.; Alami, M. Conformationnally restricted naphthalene derivatives type isocombretastatin A-4 and isoerianin analogues: Synthesis, cytotoxicity and antitubulin activity. Eur. J. Med. Chem., 2012, 52, 22-32.
89. Messaoudi, S.; Brion, J.D.; Alami, M. An Expeditious Copper- Catalyzed Access to 3-Aminoquinolinones, 3-Aminocoumarins and Anilines using Sodium Azide. Adv. Synth. Catal., 2010, 352, 1677-1687.
90. Anderson, K.; Ikawa, T.; Tundel, R.E.; Buckwald, S.L. The Selective Reaction of Aryl Halides with KOH: Synthesis of Phenols, Aromatic Ethers and Benzofurans. J. Am. Chem. Soc., 2006, 128, 10694-10695.
91. Pinney, K.G.; Mocharla, V.P.; Chen, Z.; Garner, C.M.; Ghatak, A.; Hadimani, M.; Kessler, J.; Dorsey, J.M.; Edvardsen, K.; Chaplin, D.J.; Prezioso, J.; Ghatak, U.R. Tubulin binding agents and corresponding prodrug constructs U.S. Patent Appl. 20040043969 A1, April 03, 2004.
92. Rasolofonjatovo, E.; Provot, O.; Hamze, A.; Rodrigo, J.; Bignon, Wdzieczak-Bakala, J.; Lenoir, C.; Desravines, D.; Dubois, J.; Brion, J.D.; Alami, M. Design, synthesis and anticancer properties of 5-arylbenzoxepins as conformationally restricted isocombretastatin A-4 analogs. Eur. J. Med. Chem., 2013, 62, 28-39.
93. Messaoudi, S.; Hamze, A.; Provot, O.; Tréguier, B.; Rodrigo De Losada, J.; Bignon, J.; Liu, J.M.; Wdzieczak-Bakala, J.; Thoret, S.; Dubois, J.; Brion, J.D.; Alami, M. Discovery of isoerianin analogues as promising anticancer agents. ChemMedChem, 2011, 6, 488-497.
94. Gong, Y.Q.; Fan, Y.; Wu, D.Z.; Yang, H.; Hu, Z.B.; Wang, Z.T. In vivo and in vitro evaluation of erianin, a novel anti-angiogenic agent. Eur. J. Cancer, 2004, 40, 1554-1565.
95. Schilstra, M.J.; Martin, S.R.; Bayleys, P.M. The effect of podophyllotoxin on microtubule dynamics. J. Biol. Chem., 1989, 264, 8827-8834.
96. Jordan, M.A.; Thrower, D.; Wilson, L. Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J. Cell. Sci., 1992, 102, 401-416.
97. L'Hermite, N.; Giraud, A.; Provot, O.; Peyrat, J.F.; Alami, M.; Brion, J.D. Disproportionation reaction of diarylmethylisopropyl ethers: a versatile access to diarylmethanes from diarylcarbinols speeded up by the use of microwave irradiation. Tetrahedron, 2006, 62, 11994-12002.
98. Getahun, Z.; Jurd, L.; Chu, P.S.; Lin, C.M.; Hamel, E. Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: Differential enhancement of inhibitory effects under suboptimal polymerization reaction conditions. J. Med. Chem., 1992, 35, 1058-1067.
99. Wiggins, J.M. A convenient procedure for the reduction of diarylmethanols with dichlorodimethylsilane/sodium iodide. Synth. Commun., 1988, 18, 741-749.
100. Lara-Ochoa, F.; Espinosa-Perez, G. A new synthesis of combretastatins A-4 and AVE-8062A. Tetrahedron Lett., 2007, 48, 7007-7010.
101. Pettit, G.R.; Singh, S.B.; Niven, M.L.; Hamel, E.; Schmidt, J.M. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J. Nat. Prod., 1987, 50, 119-131.
102. Dietrich, H.W.III; Wiliams, R.C.; Jr.; Macdonald, T.L.; Wilson, L.; Puett, D. Changes in the circular dichroic spectrum of colchicine associated with its binding to tubulin. Biochemistry, 1981, 20, 5999-6005.
103. O'Boyle, N.M.; Carr, M.; Greene, L.M.; Bergin, O.; Nathwani, S.M.; McCabe, T.; Llyod, D.G.; Zisterer, D.M.; Meegan, M.J. Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents. J. Med. Chem., 2010, 53, 8569-8584.
104. Huber, S.K.; Werbovetz, K.A.; Obaza-Nutaitis, J.; Lehnert, E.K.; Macdonald, T.L. Tubulin binding of conformationally restricted bis-aryl compounds. Bioorg. Med. Chem. Lett., 1991, 1, 243-246.
105. Kim, Y.; Nam, N.H.; You, Y.J.; Ahn, B.Z. Synthesis and Cytotoxicity of 3,4-Diaryl-2(5H)-furanones. Bioorg. Med. Chem. Lett., 2002, 12, 719-722.
106. Nguyen, T.L.; McGrath, C.; Hermone, A.R.; Burnett, J.C.; Zaharevitz, D.W.; Day, B.W.; Wipf, P.; Hamel, E.; Gussio, R. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J. Med. Chem., 2005, 48, 6107-6116.
107. Romagnoli, R.; Baraldi, P.G.; Carrion, M.D.; Cruz-Lopez, O.; Tolomeo, M.; Grimaudo, S.; DiChristina, A.; Pipitone, M.R.; Balzarini, J.; Brancale, A.; Hamel, E. Substituted 2-(3',4',5'- trimethoxybenzoyl)-benzo[b]thiophene derivatives as potent tubulin polymerization inhibitors. Bioorg. Med. Chem., 2010, 18, 5114-5122.
108. Odlo, K.; Hentzen, J.; Fournier dit Chabert, J.; Ducki, S.; Gani, O.A.; Sylte, I.; Skrede, M.; Florenes, V.A.; Hansen, T.V. 1,5- Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin. Bioorg. Med. Chem., 2008, 16, 4829-4838.
109. Soussi, M.A.; Aprile, S.; Messaoudi, S.; Provot, O.; Del Grosso, E.; Bignon, J.; Dubois, J.; Brion, J.D.; Grosa, G.; Alami, M. The metabolic fate of isocombretastatin A-4 in human liver microsomes: identification, synthesis and biological evaluation of metabolites. ChemMedChem, 2011, 6, 1781-1788.
110. Réjiba, S.; Reddy, L.H.; Bigand, C.; Parmentier, C.; Hajri, A. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine, 2011, 7, 841-849.
111. Reddy, L.H.; Khoury, H.; Deroussent, A.; Ferreira, H.; Dubernet, C.; Declèves, X.; Besnard, M.; Chacun, H.; Lepêtre-Mouehli, S.; Desmaële, D.; Rousseau, B.; Laugier, C.; Cintrat, J.C.; Vassal, G.; Couvreur, P. Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice. Drug Metab. Dispos., 2008, 36, 1570-1577.